These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released using the email and RSS tools below.

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

 
From
To
Nov 24, 2020
China Biologic Reports Financial Results for the Third Quarter of 2020

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...

More
Nov 19, 2020
China Biologic Enters into Definitive Merger Agreement for Going Private Transaction

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has...

More
Nov 13, 2020
China Biologic Products to Report Third Quarter 2020 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Aug 17, 2020
China Biologic Reports Financial Results for the Second Quarter of 2020

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...

More
Aug 10, 2020
China Biologic Products to Report Second Quarter 2020 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Jun 29, 2020
China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the...

More
May 20, 2020
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that Xinjiang...

More
May 20, 2020
China Biologic Reports Financial Results for the First Quarter of 2020

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...

More
May 12, 2020
China Biologic Products to Report First Quarter 2020 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Mar 12, 2020
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial...

More
Mar 3, 2020
China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Nov 13, 2019
China Biologic Reports Financial Results for the Third Quarter of 2019

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited...

More
Nov 4, 2019
China Biologic Products to Report Third Quarter 2019 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Oct 17, 2019
China Biologic Special Committee Retains Financial Advisor and Legal Counsel

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Sep 24, 2019
China Biologic Forms Special Committee to Review "Going Private" Proposal

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board...

More
Sep 18, 2019
China Biologic Announces Receipt of Preliminary Non-Binding "Going Private" Proposal

China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board...

More
Aug 5, 2019
China Biologic Reports Financial Results for the Second Quarter of 2019

--2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms -- --1H19 Total Sales Up...

More
Jul 26, 2019
China Biologic Products to Report Second Quarter 2019 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
May 10, 2019
China Biologic Reports Financial Results for the First Quarter of 2019

--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING, May 10, 2019...

More
Apr 30, 2019
China Biologic Products to Report First Quarter 2019 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Mar 6, 2019
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2018

-- 4Q18 Total Sales Up 27.5% YoY in USD terms, or 33.5% YoY in RMB terms; Net Income Up $59.4 Million YoY to $34.8 Million; Non-GAAP Adjusted Net Income Up 23.9% YoY in RMB terms -- -- FY18 Total...

More
Feb 25, 2019
China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Jan 7, 2019
China Biologic Reiterates Full Year 2018 Financial Forecast

China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today reiterated its...

More
Dec 14, 2018
China Biologic Announces Dismissal of Lawsuit Filed in Cayman Islands by Former Chairman

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the...

More
Nov 1, 2018
China Biologic Reports Financial Results for the Third Quarter of 2018

3Q18 Total Sales Up 21.9% YoY in RMB terms, or 19.6% YoY in USD terms; Non-GAAP Adjusted Net Income Down 12.7% YoY in RMB terms; Net Income Up 4.1% YoY to $32.9 Million Board of Directors Approves...

More
1-25      26-50      51-75      76-100      101-125      126-150      151-175      176-200      201-225      226-250      251-252